Budesonide, Formoterol Fumarate Drug Combination
"Budesonide, Formoterol Fumarate Drug Combination" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.
| Descriptor ID |
D000069502
|
| MeSH Number(s) |
D02.033.100.291.425.250 D02.092.063.291.425.250 D04.210.500.745.745.654.105.500 D26.310.348
|
| Concept/Terms |
Budesonide, Formoterol Fumarate Drug Combination- Budesonide, Formoterol Fumarate Drug Combination
- Budesonide Formoterol Drug Combination
- Budesonide Formoterol Fumarate Drug Combination
- Budesonide-Formoterol Drug Combination
- Combination, Budesonide-Formoterol Drug
- Drug Combination, Budesonide-Formoterol
- Budesonide-Formoterol Fumarate Drug Combination
|
Below are MeSH descriptors whose meaning is more general than "Budesonide, Formoterol Fumarate Drug Combination".
Below are MeSH descriptors whose meaning is more specific than "Budesonide, Formoterol Fumarate Drug Combination".
This graph shows the total number of publications written about "Budesonide, Formoterol Fumarate Drug Combination" by people in this website by year, and whether "Budesonide, Formoterol Fumarate Drug Combination" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 3 | 0 | 3 |
| 2018 | 1 | 0 | 1 |
| 2019 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Budesonide, Formoterol Fumarate Drug Combination" by people in Profiles.
-
Anti-inflammatory reliever therapy for asthma. Ann Allergy Asthma Immunol. 2020 01; 124(1):13-15.
-
DuoResp® Spiromax® adherence, satisfaction and ease of use: findings from a multi-country observational study in patients with asthma and COPD in Europe (SPRINT). J Asthma. 2020 10; 57(10):1110-1118.
-
The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial). COPD. 2018 Jun-Aug; 15(4):334-340.
-
Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist. Int J Chron Obstruct Pulmon Dis. 2017; 12:2477-2485.
-
Randomized Clinical Trial of a Combination of an Inhaled Corticosteroid and Beta Agonist in Patients at Risk of Developing the Acute Respiratory Distress Syndrome. Crit Care Med. 2017 May; 45(5):798-805.
-
Debate on long-acting ß agonists for asthma: they think it's all over. Lancet Respir Med. 2017 03; 5(3):e14-e15.